About Lysine-rich nucleolar protein 1
Lysine-rich nucleolar protein 1 (KNOP1) is a protein
from Homo sapiens identified by UniProt accession
Q1ED39, 458 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Lysine-rich nucleolar protein 1 |
| UniProt accession | Q1ED39 |
| Gene | KNOP1 |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.24
- waist circumference · score 0.09
- hepatocellular carcinoma · score 0.08
- late-onset Alzheimers disease · score 0.06
- body mass index · score 0.06
- platelet crit · score 0.04
- platelet count · score 0.04
- episodic ataxia type 1 · score 0.03
- isolated dystonia · score 0.03
- body height · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q1ED39-F1 | alphafold | PREDICTED | 53.41 | — |
Amino-acid sequence (458 residues)
MITKTHKVDL GLPEKKKKKK VVKEPETRYS VLNNDDYFAD VSPLRATSPS KSVAHGQAPE MPLVKKKKKK KKGVSTLCEE HVEPETTLPA RRTEKSPSLR KQVFGHLEFL SGEKKNKKSP LAMSHASGVK TSPDPRQGEE ETRVGKKLKK HKKEKKGAQD PTAFSVQDPW FCEAREARDV GDTCSVGKKD EEQAALGQKR KRKSPREHNG KVKKKKKIHQ EGDALPGHSK PSRSMESSPR KGSKKKPVKV EAPEYIPISD DPKASAKKKM KSKKKVEQPV IEEPALKRKK KKKRKESGVA GDPWKEETDT DLEVVLEKKG NMDEAHIDQV RRKALQEEID RESGKTEASE TRKWTGTQFG QWDTAGFENE DQKLKFLRLM GGFKNLSPSF SRPASTIARP NMALGKKAAD SLQQNLQRDY DRAMSWKYSR GAGLGFSTAP NKIFYIDRNA SKSVKLED
Explore Lysine-rich nucleolar protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets